Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma (Q114080993)
Jump to navigation
Jump to search
scientific article published in 2022
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma |
scientific article published in 2022 |
Statements
1 reference
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma (English)
1 reference
1 reference
1 reference
1 reference
Namiki Izumi
1 reference
Hironori Ochi
1 reference
Masayuki Kurosaki
1 reference
Kouji Joko
1 reference
Toshie Mashiba
1 reference
Hiroyuki Marusawa
1 reference
Shinichiro Nakamura
1 reference
Ryoichi Narita
1 reference
Yasushi Uchida
1 reference
Takehiro Akahane
1 reference
Masahiko Kondo
1 reference
Nami Mori
1 reference
Shintaro Takaki
1 reference
Keiji Tsuji
1 reference
Atsunori Kusakabe
1 reference
Koichiro Furuta
1 reference
Haruhiko Kobashi
1 reference
Hirotaka Arai
1 reference
Michiko Nonogi
1 reference
Takashi Tamada
1 reference
Chitomi Hasebe
1 reference
7 September 2022
1 reference
Identifiers
1 reference